Enovis (NYSE:ENOV – Get Rating) and Advanced Biomedical Technologies (OTCMKTS:ABMT – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Analyst Recommendations
This is a breakdown of current recommendations for Enovis and Advanced Biomedical Technologies, as reported by MarketBeat.
Get Enovis alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 0 | 2 | 1 | 0 | 2.33 |
| Advanced Biomedical Technologies | 0 | 0 | 0 | 0 | N/A |
Enovis currently has a consensus price target of $67.00, suggesting a potential upside of 16.12%. Given Enovis' higher possible upside, research analysts clearly believe Enovis is more favorable than Advanced Biomedical Technologies.
Profitability
This table compares Enovis and Advanced Biomedical Technologies' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Enovis | 1.77% | 6.35% | 3.57% |
| Advanced Biomedical Technologies | N/A | N/A | N/A |
Risk and Volatility
Enovis has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of -1, meaning that its stock price is 200% less volatile than the S&P 500.
Earnings & Valuation
This table compares Enovis and Advanced Biomedical Technologies' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $3.85 billion | 0.81 | $71.66 million | $1.32 | 43.71 |
| Advanced Biomedical Technologies | $120,000.00 | 35.88 | -$670,000.00 | N/A | N/A |
Enovis has higher revenue and earnings than Advanced Biomedical Technologies.
Summary
Enovis beats Advanced Biomedical Technologies on 8 of the 9 factors compared between the two stocks.
About Enovis
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
About Advanced Biomedical Technologies
(Get Rating)
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.